 Carlsbad, CA, Dec. 30, 2022 GLOBE NEWSWIRE Palisade Bio, Inc. Nasdaq: PALI, a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal GI complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 1,052,631 shares of common stock or certain pre-funded warrants in lieu thereof in ... The post Palisade Bio Announces 2.5 Million Registered Direct Offering and Concurrent Priv... 